Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study' by Zheng
| Autor: | Susan Boklage, Toshio Kimura, Gregory St John, Jeannie Choi, Kelechi Emeanuru, Carol J Etzel, Rajeshwari Punekar, Joel M. Kremer, T. Blachley, Stefano Fiore, Dimitrios A Pappas |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Necrosis Registry study First line Immunology Arthritis Disease General Biochemistry Genetics and Molecular Biology Arthritis Rheumatoid 03 medical and health sciences 0302 clinical medicine Rheumatology Internal medicine medicine Immunology and Allergy Humans In patient Registries 030203 arthritis & rheumatology Biological Products business.industry medicine.disease Clinical disease digestive system diseases 030104 developmental biology Rheumatoid arthritis Antirheumatic Agents Tumor Necrosis Factor Inhibitors medicine.symptom business |
| Zdroj: | Annals of the rheumatic diseases. 81(11) |
| ISSN: | 1468-2060 |
| Popis: | We thank Zheng et al 1 for their interest in our study2 and for providing constructive comments. They mention that even though the baseline mean Clinical Disease Activity Index (CDAI) was not statistically different, the proportion of patients with moderate or high disease at baseline was different and this could have been a key effect modifier.1 We used standardised differences to evaluate variables at baseline. Calculation of the standardised difference not only accounts for the means of the two cohorts, but also the SD. We noticed that continuous CDAI was balanced across the two therapy classes (as listed in the manuscript table 1, SD=−0.015)2 and similarly observed for categorical CDAI (low/moderate/high; SD=0.0515; results not shown … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|